Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge...
PET Or PET/CT In Recurrent Bowel Cancer: Benefit Unproven
12/13/2012
Lack of studies regarding benefit/consequences of higher diagnostic accuracy remain unclear For patients in whom a recurrence of bowel cancer is suspected, the study data currently available allow no robust conclusions as to the advantages and disadvantages of using positron emission tomography (PET), alone or in combination with computed tomography (CT)...
A new American Cancer Society study finds a strong inverse association between caffeinated coffee intake and oral/pharyngeal cancer mortality. The authors say people who drank more than four cups of caffeinated coffee per day were at about half the risk of death of these often fatal cancers compared to those who only occasionally or who never drank coffee...
Cancer Scientists Identify Liposarcoma Tumors That Respond To Chemotherapy
12/13/2012
Liposarcoma, the most common type of sarcoma, is an often lethal form of cancer that develops in fat cells. It is particularly deadly, in part, because the tumors are not consistently visible with positron emission tomography (PET) scans that use a common probe called FDG and because they frequently do not respond to chemotherapy...
Hope For Infertile Cancer Survivors Provided By Stem Cell Research
12/13/2012
Radiation and chemotherapy can pack a powerful punch against all kinds of cancers. Those who survive, however, are often left with bad news: Their treatments have rendered them infertile...
Coffee Drinking May Halve Risk Of Mouth And Throat Cancer
12/12/2012
A new study from the US finds people who drink more than 4 cups of caffeinated coffee a day have half the risk of dying from oral/pharyngeal (mouth and throat) cancer as people who drink it either occasionally or not at all...
Data from the Phase III SABRINA trial presented at the annual meeting of the American Society of Hematology (ASH) in Atlanta (BO22334) could mean that patients living with a form of blood cancer in the UK may soon be able to receive their treatment more quickly...
New Breast Cancer Drug (Perjeta) Boosts Survival When Added To The Current Gold Standard Therapy
12/12/2012
New survival data from the Phase III CLEOPATRA study, revealed at the San Antonio Breast Cancer Symposium (SABCS), demonstrate that Perjeta reduces the risk of death by 34% in patients with previously untreated advanced HER2-positive breast cancer, compared with the current gold standard of care - Herceptin and chemotherapy (docetaxel) (HR= 0.66; 95% CI 0.52-0.84)...
Child's Leukemia Cured By Her Own Re-Engineered Immune Cells
12/12/2012
Thanks to an experimental new therapy, a seven-year-old girl in the US with an aggressive form of childhood leukemia has been cured with her own re-engineered immune cells. After the treatment, her doctors could find no evidence of cancer...
New Option For Hard-To-Treat Blood Cancer
12/12/2012
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting took place December 8-11, 2012 in Atlanta...